Uncertain benefit: the public policy of approving smallpox vaccine research

American Journal of Public Health
Rosemary B Quigley

Abstract

Without an accurate assessment of the prospect of bioterrorist attack, it is especially challenging to evaluate the protocols for testing smallpox vaccines in the pediatric population. Usual regulatory mechanisms cannot shepherd research protocols with benefits that can only be characterized as "uncertain" in the face of more than minimal risk. When a protocol is placed in a government forum for analysis, the public has a unique opportunity to debate the balancing of research risks and benefits on behalf of children who are unable to assent to research themselves, as well as to express views about vaccination policy broadly. This model for review of pediatric research that may be without benefit will be especially important as challenging studies of various vaccines against a range of infectious properties, such as anthrax and severe acute respiratory syndrome (SARS), emerge.

References

Jan 1, 1992·Health Affairs·W K Mariner
Oct 1, 1970·The Journal of Infectious Diseases·J M LaneJ D Millar
Apr 1, 1971·American Journal of Epidemiology·J M Lane, J D Millar
Jun 15, 1999·JAMA : the Journal of the American Medical Association·D A HendersonK Tonat
Mar 30, 2002·The New England Journal of Medicine·Sharon E FreyUNKNOWN National Institute of Allergy and Infectious Diseases Smallpox Vaccine Study Group
Oct 3, 2002·Pediatrics·UNKNOWN Committee on Infectious Diseases. American Academy of Pediatrics
Oct 17, 2002·JAMA : the Journal of the American Medical Association·John M NeffDonald A Henderson
Nov 1, 2002·The New England Journal of Medicine·Robert Steinbrook
Jun 5, 2003·Pediatrics·Jon S AbramsonRobert S Baltimore

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Related Papers

American Journal of Preventive Medicine
Pascale M WortleyBrian Burke
JAMA : the Journal of the American Medical Association
Meryl Nass
JAMA : the Journal of the American Medical Association
Christine CaseyGina T Mootrey
© 2022 Meta ULC. All rights reserved